PRGO - Perrigo Company plc

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $36.20 DETAILS

Stock News

Perrigo Co PLC (PRGO) Stock Up 3.9% and Still Undervalued -- GF Score: 60/100

On October 09, 2026, Perrigo Co PLC (PRGO) shares rose by 3.9%, bringing the current price to $15.06. This movement is notable within the context of its 52-week

Oct 09, 2026 04:00 PM • gurufocus.com

Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?

Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Sep 25, 2026 04:35 AM • zacks.com

Squarepoint Ops LLC Cuts Position in Perrigo Company plc $PRGO

Squarepoint Ops LLC reduced its stake in shares of Perrigo Company plc (NYSE: PRGO) by 95.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,900 shares of the company's stock after selling 443,842 shares during the quarter.

Sep 24, 2026 11:29 PM • defenseworld.net

Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Sep 04, 2026 08:37 AM • zacks.com

Perrigo to Attend the Barclays Global Consumer Conference

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10th, 2026. About Perrigo   Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe.

Aug 27, 2026 04:30 AM • prnewswire.com

PRGO or NEOG: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?

Aug 26, 2026 08:41 AM • zacks.com

Should Value Investors Buy Perrigo (PRGO) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Aug 26, 2026 06:41 AM • zacks.com

My Top 5 Dividend Picks For August

I present my August top 5 dividend picks: PRGO, MZTI, NEE, TROW, and VICI, all rated Buy or Strong Buy for rising income and appreciation. Each pick trades at a significant discount to fair value (average 21.5%), offering an expected 5-year compound annual total return of ~12.5% and a 5.22% yield. PRGO, MZTI, and VICI stand out for deep undervaluation and robust dividend growth, with VICI offering a projected 15.8% CAGR and strong inflation-linked lease structures.

Aug 24, 2026 12:37 AM • seekingalpha.com

Perrigo: The Rebound Is Just Getting Started

Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.

Aug 13, 2026 03:30 AM • seekingalpha.com

PRGO vs. NEOG: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?

Aug 10, 2026 08:41 AM • zacks.com

Are Investors Undervaluing Perrigo (PRGO) Right Now?

Aug 10, 2026 06:41 AM • zacks.com

Perrigo Q2 Earnings Call Highlights

Perrigo NYSE: PRGO reported second-quarter 2026 results that exceeded its internal earnings expectations, while sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving category trends, market-share gains and expected second-half contributions from innovation, distribution and demand-generation efforts.

Aug 08, 2026 05:04 PM • marketbeat.com

Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates

PRGO tops Q2 EPS estimates as Infant Formula sales jump, helping offset softer demand and divestiture impacts while the company reaffirms 2026 guidance.

Aug 06, 2026 11:56 AM • zacks.com

Perrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript

Aug 05, 2026 10:00 AM • seekingalpha.com

Perrigo (PRGO) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Aug 05, 2026 06:31 AM • zacks.com

Perrigo (PRGO) Surpasses Q2 Earnings and Revenue Estimates

Perrigo (PRGO) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.57 per share a year ago.

Aug 05, 2026 04:46 AM • zacks.com

Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations

Execution of Three-S plan driving continued improvement in underlying business fundamentals, including market share growth in U.S. store-brand OTC and key European brands Streamlined portfolio through completion of Dermacosmetics divestiture and continuing strategic reviews of Infant Formula and Oral Care businesses Reaffirmed full-year 2026 outlook with sequentially stronger second-half performance DUBLIN, Aug. 5, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the second quarter ended June 27, 2026. "We continued to execute our Three-S plan in the second quarter, strengthening areas of the business within our control, improving operational performance, streamlining our portfolio, and further reducing debt," said Albert Manzone, Interim President and Chief Executive Officer.

Aug 05, 2026 02:30 AM • prnewswire.com

Perrigo Announces Quarterly Dividend

DUBLIN, July 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on September 15, 2026, to shareholders of record on August 28, 2026.

Jul 30, 2026 04:30 AM • prnewswire.com

Perrigo to Present at the Canaccord 46th Annual Growth Conference

DUBLIN, July 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to present at the Canaccord 46th Annual Growth Conference, on Wednesday, August 12th at 10:30 AM EDT. The webcast can be accessed on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.

Jul 29, 2026 04:30 AM • prnewswire.com

Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026

DUBLIN, July 22, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that it plans to release its second quarter 2026 financial results on Wednesday, August 5th, 2026. The company will hold a conference call beginning at 8:30 a.m.

Jul 22, 2026 04:30 AM • prnewswire.com